# Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.

> **NCT00267358** · PHASE2 · COMPLETED · sponsor: **Helsinn Therapeutics (U.S.), Inc**

## Conditions studied

- Cancer Cachexia

## Interventions

- **DRUG:** RC-1291 HCl
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00267358
- **Lead sponsor:** Helsinn Therapeutics (U.S.), Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** — (—)
- **Last updated:** 2013-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00267358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00267358, "Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00267358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*